Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
R&D progress on the rise
Pharmaceutical R&D saw sustained growth in clinical trial activity and a record number of novel active substances launched in 2021, according to a new report from IQVIA.
Pursuing a pathway of preventative medicine
A world without illness or disease sounds like a far-off fantasy, but some players in the pharmaceutical industry are investigating how to transform this vision into a reality.
Pharma in China
As China enters the year of the tiger – a symbol of strength and bravery – GOLD journeys to this powerhouse nation to explore how it has become the second largest pharmaceutical market in the world
Renewed focus on patient adherence
Patient adherence is the focus of a new project launched by the Innovative Medicines Initiative (IMI) and led by Pfizer.
Cancer treatment collaboration announced
Queen’s University Belfast has entered into a collaboration and licensing agreement with Ipsen to research, develop, manufacture and commercialise FLIP inhibitors.
Ripples of change in R&D
How can pharma companies improve inclusivity across their R&D cycles?
The biotech boom: fad or forever?
Biotechs have stood as agile hubs for drug discovery, but now they are being coveted by investors.
Standing out in a crowd of digital content
The amount of digital content being created for healthcare professionals has grown exponentially. Medical affairs teams must find a way to cut through the noise with their communications
A cautionary tale of digital transformation
As the pharmaceutical industry embraces digital transformation, new technologies have the potential to sink or swim. How can the industry ensure it’s backing the most effective innovations and not getting stuck in dead ends?
The future of pharmaceutical sales
The COVID-19 pandemic has reshaped pharmaceutical sales, moving from face-to-face to predominantly digital interactions. How can sales reps adapt to multichannel approaches and enhance performance amidst this shift in sales training and team dynamics?
←
1
2
3
…
13
14
15
16
17
18
19
20
21
22
→
We’ve noticed you’re accessing
from
North/South America.
View
View